BACE1 and Alzheimer disease: Taken together, the results support the idea that future clinical trials should be optimized by initiating BACE1 inhibitor interventions at the earliest preclinical stages of AD, targeting safe levels of reduction in β‐secretase activity (50% or less), and applying more sensitive memory paradigms such as accelerated long‐term forgetting.